Plasma metabolomics and incident major adverse cardiovascular events in patients with rheumatoid arthritis
In brief
Small HDL particles associate with lower cardiovascular event risk in rheumatoid arthritis
In a cohort of 1,271 RA patients without prior heart disease, higher concentrations of small HDL particles and related lipids were linked to a reduced incidence of major cardiovascular events over nearly eight years, while triglyceride-rich lipoproteins predicted higher risk. The metabolomic profile differed from matched non-RA controls, suggesting potential targets for inflammation-focused or HDL-modifying therapies, though clinical impact remains to be tested.
- Journal
- Rheumatology (Oxford, England) (Q1)
- Published
- 31 July 2026
- Study design
- Case-control study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Christos P Kotanidis, Priyam Choksi, Pradeep Natarajan, Jessica Lasky-Su, Anand Rohatgi, Elizabeth Karlson, et al.
- PMID
- 42538831
- DOI
- 10.1093/rheumatology/keag383
Why clinicians should know about it
- Picked for Rheumatology (paper of the day, 2 August 2026): Distinct cardiovascular risk profile in RA patients
Abstract
OBJECTIVES: Patients with rheumatoid arthritis (RA) have excess cardiovascular risk beyond traditional factors. We evaluated associations between plasma metabolites and incident major adverse cardiovascular events (MACE) in RA and compared findings with matched controls. METHODS: We studied 1,271 Mass General Brigham Biobank participants with RA, without known cardiovascular disease, and no statin use at blood draw. 1H-NMR metabolomics quantified 168 metabolites spanning lipoprotein particles and contents, fatty acids, amino acids, and glycolysis. Incident MACE (myocardial infarction, stroke, transient ischemic attack, or death) was identified using ICD codes. Multivariable Cox models with false discovery rate correction assessed associations. Findings were compared with a 1:2 matched non-RA control cohort. RESULTS: The mean age was 62 years, 80% were women, and 8% experienced incident MACE over a median follow-up of 7.8 years. Twenty-five plasma metabolites were significantly associated with MACE. Lower MACE risk was primarily associated with higher levels of small HDL particle concentration and lipid content, as well as circulating albumin and select amino acids. In contrast, higher MACE risk was strongly associated with triglyceride-rich and remnant-like lipoprotein measures. When compared with controls, several associations were unique to the RA patients, who demonstrated a distinct metabolomic risk profile, involving triglyceride-rich VLDL and HDL particles. CONCLUSION: In this first metabolomic study in RA, we identified a distinct cardiovascular risk profile. Higher levels of large HDL particles were associated with increased risk, whereas small HDL particles were associated with lower risk, with potential implications for inflammation-targeted and HDL-modifying therapies.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.